Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Operating Expenses (2020 - 2023)

Cullinan Therapeutics has reported Operating Expenses over the past 4 years, most recently at $45.5 million for Q4 2023.

  • Quarterly results put Operating Expenses at $45.5 million for Q4 2023, up 39.49% from a year ago — trailing twelve months through Dec 2023 was $190.6 million (up 44.28% YoY), and the annual figure for FY2025 was $241.6 million, up 22.71%.
  • Operating Expenses for Q4 2023 was $45.5 million at Cullinan Therapeutics, up from $44.8 million in the prior quarter.
  • Over the last five years, Operating Expenses for CGEM hit a ceiling of $62.8 million in Q1 2023 and a floor of $5.5 million in Q1 2020.
  • Median Operating Expenses over the past 4 years was $31.2 million (2022), compared with a mean of $29.4 million.
  • Biggest five-year swings in Operating Expenses: surged 217.11% in 2021 and later decreased 5.06% in 2022.
  • Cullinan Therapeutics' Operating Expenses stood at $29.2 million in 2020, then increased by 17.74% to $34.3 million in 2021, then dropped by 5.06% to $32.6 million in 2022, then surged by 39.49% to $45.5 million in 2023.
  • The last three reported values for Operating Expenses were $45.5 million (Q4 2023), $44.8 million (Q3 2023), and $37.6 million (Q2 2023) per Business Quant data.